Zhanqi Liu
Scientist
Andrew Scott Lab Ludwig Center at Melbourne
Ludwig Institute for Cancer Research
Australia
Biography
My research centers upon the generation and functional activity of tumor-targeting monoclonal antibodies (mAbs) for use as novel therapeutic agents. In addition to selective binding to tumor targets, recombinant chimeric and humanized mAbs can also possess functional activity through immune effector activity of ADCC and CDC, and interfere with tumor cell processes such as intracellular signaling. Deciphering the mAbs potency preclinically and developing appropriate pharmacokinetic and pharmacodynamic clinical assessments are crucial to our ability to successfully conduct Phase I clinical trials with our novel mAbs. We have more than 30 publications in leading cancer research journals.
Research Interest
Tumour cell growth, diagnosis and therapy of cancer
Publications
-
Liu, Zhanqi, et al. "Anti-renal cell carcinoma chimeric antibody G250: cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity." Cancer Immunology, Immunotherapy 51.3 (2002): 171.
-
Scott, Andrew M., et al. "Construction, production, and characterization of humanized anti-Lewis Y monoclonal antibody 3S193 for targeted immunotherapy of solid tumors." Cancer Research 60.12 (2000): 3254-3261.
-
Scott, Andrew M., et al. "A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors." Proceedings of the National Academy of Sciences 104.10 (2007): 4071-4076.
